Pacers lift curtain on $50M downtown training complex
The St. Vincent Center combines team training facilities—including regulation-sized courts, cushy recovery amenites and an underwater treadmill—with health care services for the public.
Health Care Businesses
Articles
Anthem to stop selling individual plans in much of Virginia
Anthem's departure—along with Aetna and UnitedHealthcare—means only one insurer will offer individual plans in more than half of Virginia's counties and independent cities next year.
Trump lashes out after Merck exec resigns from president’s council
President Donald Trump criticized drug prices immediately after Merck & Co.’s CEO quit the president’s council of manufacturing executives Monday, to take a “stand against intolerance and extremism.”
Lilly, other drug giants hunt for patients in India’s remote corners
Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
Lilly to pay up to $400M to buy rights for early-stage immune drug
The deal is Eli Lilly and Co.’s latest push into a growing disease area for such disorders as arthritis, lupus and multiple sclerosis.
Home Health Depot acquired by Florida-based Lincare
Home Health Depot became one of the country’s fastest-growing medical companies under the leadership of former equipment sales rep David Hartley and ex-Indiana Commerce Secretary Nate Feltman.
British Supreme Court rules in Eli Lilly’s favor in drug dispute
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
St. Vincent unveils first of four planned micro-hospitals
The scale is small, and that’s what St. Vincent Health sees as a big selling point to its newest hospital: convenience and quick care—15 minutes or less to see a doctor, and just a few minutes from home for people who live in Noblesville.
Lilly, Purdue seek medical advancements in new $52M collaboration
Eli Lilly and Co. announced the “strategic research collaboration” Thursday morning, calling it the largest agreement of its kind between Purdue and a single company.
Performance gap widening in some generic drugs, researchers say
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
Lilly, Pfizer get boost for non-opioid pain drug
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
Pharmakon owner, compliance director face criminal charges
The owner and the director of compliance for Noblesville-based Pharmakon Pharmaceuticals Inc. have been charged with multiple criminal counts related to the sale of over-potent compounded painkillers that sickened at least three infants.
Senate health plan relies on subsidies GOP has faulted
The proposal would provide an additional $50 billion over four years to stabilize insurance exchanges, relying on a mechanism Republicans have criticized in the past as a way to keep insurers in the marketplace.
Drugmaker cashing in on opioid epidemic, one state law at a time
In statehouses across the country and in Congress, drugmaker Alkermes is pushing its own addiction treatment while contributing to misconceptions and stigma about other medications used to treat opioid addiction.
First bellwether trial for ‘low-T’ treatment could have ramifications for Lilly
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
St. Vincent system to cut 111 jobs in outsourcing move
Most of the cuts this summer will come from the hospital system’s billing operations in Indianapolis.
Drugmakers brace for Trump proposals to tackle U.S. prices
Top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
Former IU Health CEO to join law firm’s consulting arm
Dan Evans, who for 13 years was president and CEO of Indiana University Health, has joined Faegre Baker Daniels Consulting as a senior director in its health and biosciences group.
Lilly migraine drug provides relief in late-stage trials
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
Drug lobby mulling membership reductions amid price scrutiny
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.